ConductScience.org, home

Paper28107479

Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate.

Mpakou V and 13 others. PLoS One, 2017. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate. Papers, record 28107479. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28107479

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate.
PubMed
Journal
PLoS One
PubMed
Year
2017
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.23
iCite
Revised in PubMed
2018-11-13
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mpakou VVassiliki
2Papadavid EEvangelia
3Kontsioti FFrieda
4Konsta EEugene
5Vikentiou MMiriam
6Spathis AAris
7Papageorgiou SSotiris
8Vasilatou DDiamantina
9Gkontopoulos KKonstantinos
10Mpazani EEfthimia
11Karakitsos PPetros
12Rigopoulos DDimitrios
13Dimitriadis GGeorge
14Pappa VVasilikihttps://orcid.org/0000-0003-0421-9424

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
ApoptosisMajor topic
BortezomibMajor topic
Gene Expression ProfilingMajor topic
Lymphoma, T-Cell, CutaneousMajor topic
MethotrexateMajor topic
Cell Line, Tumor
DNA Repair
Flow Cytometry
Humans
Polymerase Chain Reaction
Signal Transduction

Source PubMed

Download CSV of topics

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
114202592OBSERVATIONS ON THE USE OF CANCER CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH MYCOSIS FUNGOIDES.Cancer1964https://conductscience.org/library/papers/14202592PubMed
21918470The pharmacology of methotrexate.J Am Acad Dermatol1991https://conductscience.org/library/papers/1918470PubMed
319741722Proteasome inhibitors in the treatment of multiple myeloma.Leukemia2009https://conductscience.org/library/papers/19741722PubMed
421224428Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.Mol Cancer Res2011https://conductscience.org/library/papers/21224428PubMed
525629353DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining.PLoS Genet2015https://conductscience.org/library/papers/25629353PubMed
68601652Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients.J Am Acad Dermatol1996https://conductscience.org/library/papers/8601652PubMed
719274461Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents.Cancer Chemother Pharmacol2009https://conductscience.org/library/papers/19274461PubMed
819201084The vital link between the ubiquitin-proteasome pathway and DNA repair: impact on cancer therapy.Cancer Lett2009https://conductscience.org/library/papers/19201084PubMed
921576575The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides.Arch Dermatol2011https://conductscience.org/library/papers/21576575PubMed
1014576667Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients.J Am Acad Dermatol2003https://conductscience.org/library/papers/14576667PubMed
1115692063WHO-EORTC classification for cutaneous lymphomas.Blood2005https://conductscience.org/library/papers/15692063PubMed
1223181572From bortezomib to other inhibitors of the proteasome and beyond.Curr Pharm Des2013https://conductscience.org/library/papers/23181572PubMed
1319016373Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.J Dermatolog Treat2009https://conductscience.org/library/papers/19016373PubMed
1423045584Emerging treatment options for advanced-stage mycosis fungoides.J Clin Oncol2012https://conductscience.org/library/papers/23045584PubMed
1525336628Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy.Blood2015https://conductscience.org/library/papers/25336628PubMed
1611306489The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.Cancer Res2001https://conductscience.org/library/papers/11306489PubMed
1718158775Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.Cancer Biother Radiopharm2007https://conductscience.org/library/papers/18158775PubMed
1825305590A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.J Proteomics2015https://conductscience.org/library/papers/25305590PubMed
1922377766MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.J Invest Dermatol2012https://conductscience.org/library/papers/22377766PubMed
2025592781Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.Hematology2015https://conductscience.org/library/papers/25592781PubMed

See all 60 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42823576Polymeric micelle delivery of a HER2-selective tyrosine kinase inhibitor for targeted breast cancer therapy.Drug Deliv Transl Res2026https://conductscience.org/library/papers/42823576PubMed
33313939Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.Acta Derm Venereol2021https://conductscience.org/library/papers/33313939PubMed
30993483Cell-type-specific sensitivity of bortezomib in the methotrexate-resistant primary central nervous system lymphoma cells.Int J Clin Oncol2019https://conductscience.org/library/papers/30993483PubMed
29572582Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.Curr Oncol Rep2018https://conductscience.org/library/papers/29572582PubMed

Download CSV of cited by

Genes50

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ANXA5308PubTator's text mininghttps://conductscience.org/library/genes/308NCBI Gene
ATM472PubTator's text mininghttps://conductscience.org/library/genes/472NCBI Gene
ATR545PubTator's text mininghttps://conductscience.org/library/genes/545NCBI Gene
BCL3602PubTator's text mininghttps://conductscience.org/library/genes/602NCBI Gene
BIRC2329PubTator's text mininghttps://conductscience.org/library/genes/329NCBI Gene
BIRC3330PubTator's text mininghttps://conductscience.org/library/genes/330NCBI Gene
BRCA1672PubTator's text mininghttps://conductscience.org/library/genes/672NCBI Gene
BRCA2675PubTator's text mininghttps://conductscience.org/library/genes/675NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CDK71022PubTator's text mininghttps://conductscience.org/library/genes/1022NCBI Gene
CXCL83576PubTator's text mininghttps://conductscience.org/library/genes/3576NCBI Gene
CXCR47852PubTator's text mininghttps://conductscience.org/library/genes/7852NCBI Gene
DDB21643PubTator's text mininghttps://conductscience.org/library/genes/1643NCBI Gene
DHFR1719PubTator's text mininghttps://conductscience.org/library/genes/1719NCBI Gene
ERCC12067PubTator's text mininghttps://conductscience.org/library/genes/2067NCBI Gene
ERCC62074PubTator's text mininghttps://conductscience.org/library/genes/2074NCBI Gene
FANCC2176PubTator's text mininghttps://conductscience.org/library/genes/2176NCBI Gene
FANCM57697PubTator's text mininghttps://conductscience.org/library/genes/57697NCBI Gene
FAS355PubTator's text mininghttps://conductscience.org/library/genes/355NCBI Gene
H3P16644914PubTator's text mininghttps://conductscience.org/library/genes/644914NCBI Gene

See all 50 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28107479

GET https://conductscience.org/api/papers/v1/28107479/references?page=2